Myxoma virus suppresses proliferation of activated T lymphocytes yet permits oncolytic virus transfer to cancer cells

Nancy Villa, Clive H. Wasserfall, Amy M. Meacham, Elizabeth Wise, Winnie Chan, John R. Wingard, Douglas McFadden, Christopher R. Cogle

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Allogeneic hematopoietic cell transplant (allo-HCT) can be curative for certain hematologic malignancies, but the risk of graft-versus-host disease (GVHD) is a major limitation for wider application. Ideally, strategies to improve allo-HCT would involve suppression of T lymphocytes that drive GVHD while sparing those that mediate graft-versus-malignancy (GVM). Recently, using a xenograft model, we serendipitously discovered that myxoma virus (MYXV) prevented GVHD while permitting GVM. In this study, we show that MYXV binds to resting, primary human T lymphocytes but will only proceed into active virus infection after the T cells receive activation signals. MYXV-infected T lymphocytes exhibited impaired proliferation after activation with reduced expression of interferon-γ, interleukin-2 (IL-2), and soluble IL-2Rα, but did not affect expression of IL-4 and IL-10. MYXV suppressed T-cell proliferation in 2 patterns (full vs partial) depending on the donor. In terms of GVM, we show that MYXV-infected activated human T lymphocytes effectively deliver live oncolytic virus to human multiple myeloma cells, thus augmenting GVM by transfer of active oncolytic virus to residual cancer cells. Given this dual capacity of reducing GVHD plus increasing the antineoplastic effectiveness of GVM, ex vivo virotherapy with MYXV may be a promising clinical adjunct to allo-HCT regimens.

Original languageEnglish (US)
Pages (from-to)3778-3788
Number of pages11
JournalBlood
Volume125
Issue number24
DOIs
StatePublished - Jun 11 2015
Externally publishedYes

Fingerprint

Myxoma virus
Oncolytic Viruses
T-cells
Viruses
Grafts
Cells
T-Lymphocytes
Transplants
Graft vs Host Disease
Neoplasms
Chemical activation
Residual Neoplasm
Virus Diseases
Hematologic Neoplasms
Multiple Myeloma
Heterografts
Cell proliferation
Interleukin-4
Antineoplastic Agents
Interleukin-10

ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology

Cite this

Villa, N., Wasserfall, C. H., Meacham, A. M., Wise, E., Chan, W., Wingard, J. R., ... Cogle, C. R. (2015). Myxoma virus suppresses proliferation of activated T lymphocytes yet permits oncolytic virus transfer to cancer cells. Blood, 125(24), 3778-3788. https://doi.org/10.1182/blood-2014-07-587329

Myxoma virus suppresses proliferation of activated T lymphocytes yet permits oncolytic virus transfer to cancer cells. / Villa, Nancy; Wasserfall, Clive H.; Meacham, Amy M.; Wise, Elizabeth; Chan, Winnie; Wingard, John R.; McFadden, Douglas; Cogle, Christopher R.

In: Blood, Vol. 125, No. 24, 11.06.2015, p. 3778-3788.

Research output: Contribution to journalArticle

Villa, Nancy ; Wasserfall, Clive H. ; Meacham, Amy M. ; Wise, Elizabeth ; Chan, Winnie ; Wingard, John R. ; McFadden, Douglas ; Cogle, Christopher R. / Myxoma virus suppresses proliferation of activated T lymphocytes yet permits oncolytic virus transfer to cancer cells. In: Blood. 2015 ; Vol. 125, No. 24. pp. 3778-3788.
@article{5905b56f8cf24bc7a92036dd4cff9c58,
title = "Myxoma virus suppresses proliferation of activated T lymphocytes yet permits oncolytic virus transfer to cancer cells",
abstract = "Allogeneic hematopoietic cell transplant (allo-HCT) can be curative for certain hematologic malignancies, but the risk of graft-versus-host disease (GVHD) is a major limitation for wider application. Ideally, strategies to improve allo-HCT would involve suppression of T lymphocytes that drive GVHD while sparing those that mediate graft-versus-malignancy (GVM). Recently, using a xenograft model, we serendipitously discovered that myxoma virus (MYXV) prevented GVHD while permitting GVM. In this study, we show that MYXV binds to resting, primary human T lymphocytes but will only proceed into active virus infection after the T cells receive activation signals. MYXV-infected T lymphocytes exhibited impaired proliferation after activation with reduced expression of interferon-γ, interleukin-2 (IL-2), and soluble IL-2Rα, but did not affect expression of IL-4 and IL-10. MYXV suppressed T-cell proliferation in 2 patterns (full vs partial) depending on the donor. In terms of GVM, we show that MYXV-infected activated human T lymphocytes effectively deliver live oncolytic virus to human multiple myeloma cells, thus augmenting GVM by transfer of active oncolytic virus to residual cancer cells. Given this dual capacity of reducing GVHD plus increasing the antineoplastic effectiveness of GVM, ex vivo virotherapy with MYXV may be a promising clinical adjunct to allo-HCT regimens.",
author = "Nancy Villa and Wasserfall, {Clive H.} and Meacham, {Amy M.} and Elizabeth Wise and Winnie Chan and Wingard, {John R.} and Douglas McFadden and Cogle, {Christopher R.}",
year = "2015",
month = "6",
day = "11",
doi = "10.1182/blood-2014-07-587329",
language = "English (US)",
volume = "125",
pages = "3778--3788",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "24",

}

TY - JOUR

T1 - Myxoma virus suppresses proliferation of activated T lymphocytes yet permits oncolytic virus transfer to cancer cells

AU - Villa, Nancy

AU - Wasserfall, Clive H.

AU - Meacham, Amy M.

AU - Wise, Elizabeth

AU - Chan, Winnie

AU - Wingard, John R.

AU - McFadden, Douglas

AU - Cogle, Christopher R.

PY - 2015/6/11

Y1 - 2015/6/11

N2 - Allogeneic hematopoietic cell transplant (allo-HCT) can be curative for certain hematologic malignancies, but the risk of graft-versus-host disease (GVHD) is a major limitation for wider application. Ideally, strategies to improve allo-HCT would involve suppression of T lymphocytes that drive GVHD while sparing those that mediate graft-versus-malignancy (GVM). Recently, using a xenograft model, we serendipitously discovered that myxoma virus (MYXV) prevented GVHD while permitting GVM. In this study, we show that MYXV binds to resting, primary human T lymphocytes but will only proceed into active virus infection after the T cells receive activation signals. MYXV-infected T lymphocytes exhibited impaired proliferation after activation with reduced expression of interferon-γ, interleukin-2 (IL-2), and soluble IL-2Rα, but did not affect expression of IL-4 and IL-10. MYXV suppressed T-cell proliferation in 2 patterns (full vs partial) depending on the donor. In terms of GVM, we show that MYXV-infected activated human T lymphocytes effectively deliver live oncolytic virus to human multiple myeloma cells, thus augmenting GVM by transfer of active oncolytic virus to residual cancer cells. Given this dual capacity of reducing GVHD plus increasing the antineoplastic effectiveness of GVM, ex vivo virotherapy with MYXV may be a promising clinical adjunct to allo-HCT regimens.

AB - Allogeneic hematopoietic cell transplant (allo-HCT) can be curative for certain hematologic malignancies, but the risk of graft-versus-host disease (GVHD) is a major limitation for wider application. Ideally, strategies to improve allo-HCT would involve suppression of T lymphocytes that drive GVHD while sparing those that mediate graft-versus-malignancy (GVM). Recently, using a xenograft model, we serendipitously discovered that myxoma virus (MYXV) prevented GVHD while permitting GVM. In this study, we show that MYXV binds to resting, primary human T lymphocytes but will only proceed into active virus infection after the T cells receive activation signals. MYXV-infected T lymphocytes exhibited impaired proliferation after activation with reduced expression of interferon-γ, interleukin-2 (IL-2), and soluble IL-2Rα, but did not affect expression of IL-4 and IL-10. MYXV suppressed T-cell proliferation in 2 patterns (full vs partial) depending on the donor. In terms of GVM, we show that MYXV-infected activated human T lymphocytes effectively deliver live oncolytic virus to human multiple myeloma cells, thus augmenting GVM by transfer of active oncolytic virus to residual cancer cells. Given this dual capacity of reducing GVHD plus increasing the antineoplastic effectiveness of GVM, ex vivo virotherapy with MYXV may be a promising clinical adjunct to allo-HCT regimens.

UR - http://www.scopus.com/inward/record.url?scp=84931281752&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84931281752&partnerID=8YFLogxK

U2 - 10.1182/blood-2014-07-587329

DO - 10.1182/blood-2014-07-587329

M3 - Article

VL - 125

SP - 3778

EP - 3788

JO - Blood

JF - Blood

SN - 0006-4971

IS - 24

ER -